Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company is based in Ras al-Khaimah, the United Arab Emirates. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.
Apimeds Pharmaceuticals US, Inc. (APUS) - Total Assets
Latest total assets as of September 2025: $9.25 Million USD
Based on the latest financial reports, Apimeds Pharmaceuticals US, Inc. (APUS) holds total assets worth $9.25 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Apimeds Pharmaceuticals US, Inc. - Total Assets Trend (2021–2024)
This chart illustrates how Apimeds Pharmaceuticals US, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Apimeds Pharmaceuticals US, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Apimeds Pharmaceuticals US, Inc.'s total assets of $9.25 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 26.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Apimeds Pharmaceuticals US, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Apimeds Pharmaceuticals US, Inc.'s current assets represent 100.0% of total assets in 2024, unchanged from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 26.5% of total assets in 2024, down from 99.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Apimeds Pharmaceuticals US, Inc. Competitors by Total Assets
Key competitors of Apimeds Pharmaceuticals US, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Apimeds Pharmaceuticals US, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Apimeds Pharmaceuticals US, Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Apimeds Pharmaceuticals US, Inc. is currently not profitable relative to its asset base.
Apimeds Pharmaceuticals US, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.34 | 0.05 | 0.02 |
| Quick Ratio | 8.34 | 0.05 | 0.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.00 Million | $ -724.49K | $ -313.61K |
Apimeds Pharmaceuticals US, Inc. - Advanced Valuation Insights
This section examines the relationship between Apimeds Pharmaceuticals US, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.17 |
| Latest Market Cap to Assets Ratio | 260.29 |
| Asset Growth Rate (YoY) | -96.9% |
| Total Assets | $13.06K |
| Market Capitalization | $3.40 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Apimeds Pharmaceuticals US, Inc.'s assets at a significant premium ( 260.29x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Apimeds Pharmaceuticals US, Inc.'s assets decreased by 96.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Apimeds Pharmaceuticals US, Inc. (2021–2024)
The table below shows the annual total assets of Apimeds Pharmaceuticals US, Inc. from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $13.06K | -96.91% |
| 2023-12-31 | $422.08K | +6739.67% |
| 2022-12-31 | $6.17K | -96.42% |
| 2021-12-31 | $172.17K | -- |